Custom RNA vaccines take on aggressive breast cancer in first human test
NCT ID NCT02316457
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This first-in-human trial tested personalized RNA vaccines designed to target each patient's unique tumor mutations in triple negative breast cancer (TNBC). 42 participants received two custom-made vaccines to stimulate their immune system. The main goal was to check safety and tolerability, with secondary focus on immune response. The study is completed, but results are not yet widely available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized RNA vaccine (IVAC_W_bre1_uID and IVAC_M_uID)
- What this could lead to
- If successful, this approach could lead to a personalized immunotherapy that trains the immune system to fight triple negative breast cancer, potentially improving outcomes for patients with this aggressive cancer.
- What could go wrong
- This is an early Phase 1 trial focused on safety, not effectiveness. The vaccines are custom-made for each patient, which is complex and may not work for everyone. Side effects or limited immune response are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.